Clinical Trials in San Antonio

Showing 3181-3200 of 12,572 trials

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

NCT02279433

DS-6051b is an orally administered inhibitor of the tyrosine kinases (ROS1) and neurotropic tyrosine kinase receptors (NTRK). This phase 1 first-in-human study evaluates safety and tolerability of DS-6051b in cancer subjects and identify a recommended phase 2 dose (RP2D). In addition, this study will also assess the pharmacokinetic (PK)/pharmacodynamic (PD) profiles and preliminary efficacy of DS-6051b.

Solid Tumors

Nuvation Bio Inc.46 participantsStarted Sep 2014

Scottsdale, Arizona, United States • Orange, California, United States • Boston, Massachusetts, United States +3 more locations

COMPLETEDPhase 1< 1 mile

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

NCT05134662

This is a Phase 1, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALT-801 and its effects on glucose control in overweight and obese subjects with type 2 diabetes mellitus (T2DM).

Type 2 Diabetes

Altimmune, Inc.55 participantsStarted Feb 2022

Fort Myers, Florida, United States • Sarasota, Florida, United States • River Forest, Illinois, United States +4 more locations

Active Not RecruitingPhase 3< 1 mile

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

NCT05795699

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Fuchs Endothelial Corneal Dystrophy

Kowa Research Institute, Inc.107 participantsStarted Mar 2023

Los Angeles, California, United States • Los Angeles, California, United States • Los Angeles, California, United States +47 more locations

A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b

ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)

Find Trials by Condition in San Antonio

Behavioral Economic Intervention to Improve HIV Behaviors in Sexual Minority Individuals

Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®

Shared Decision Making in PTSD Treatment

A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Wound Healing Following Tooth Extraction and Ridge Preservation Using DFDBA Alone in Particulate Fiber Form and in Combination With Xenograft

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration (i-SIGHT)

National Collaborative to Improve Care of Children With Complex Congenital Heart Disease

A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.

Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Open-label Treatment in Cushing's Syndrome

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

International Rare Histiocytic Disorders Registry (IRHDR)

A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection